GSK/Novartis transaction

We recently announced a major three-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses. More details can be found below.

We have released a circular to shareholders and notice of general meeting relating to the transaction.  GSK held a General Meeting to approve the proposed major transaction with Novartis AG on 18 December 2014.

The proposed transaction would substantially strengthen two of our core businesses in vaccines and consumer healthcare and creates significant new options to increase value for shareholders. It is the most significant transaction for the Company since the creation of GSK in 2000 and is a major step towards fulfilling the Company’s strategy of creating a simpler, stronger and more balanced platform for long-term growth.

25 – December -2014